I believe your premise "will the FDA ever approve Leronlimab with Nader Pourhassan as CytoDyn CEO?" is a distraction.
It's not a matter of them liking/disliking NP at all.
It's all about who has control over Leronlimab!
If leronlimab is controlled by someone "willing to play footsie with the other members of big pharma - Okay!"
Why? Leronlimab is a "game-changer" potentially affecting billions of dollars of future potential profit.
The key is safety - leronlimab is surprisingly safe, in fact it's unique in that respect!
Leronlimab could wipe out future BP profits in a number of arenas. Its amazing number of potential indications and its SAFETY...
are a HUGE THREAT TO PHARMAS FUTURE PROSPECTS ALONG WITH PROFITS! When it comes to BP it's down to "pipeline" - what drugs do they have still making nice profits, how long before the generics can cut into their action, what is the "pipeline coming up," where is the next wonder drug coming from?
Leronlimab increases the challenge for BP companies exponentially. Besides what drugs do their companies have "coming up" - now they have to worry about efficacy AND SAFETY or be "second-rate" compared to leronlimab's efficacy and established safety.
UNFORTUNATELY (in the view of BP)
Right now Leronlimab is in the hands of a "rogue operator" [read NP}] and a "rogue company" (read CytoDyn Inc.) outside of BP's control and NOT PLAYING FOOTSIE! WITH BP!!!
This has to end NOW! ...enter the 13d team.
News 
Market Data 
Discover 
